Canada Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Canada recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Canada recombinant protein therapeutics cdmo market highlights
- The Canada recombinant protein therapeutics cdmo market generated a revenue of USD 1,174.3 million in 2023 and is expected to reach USD 2,764.0 million by 2030.
- The Canada market is expected to grow at a CAGR of 13% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
Recombinant protein therapeutics cdmo market data book summary
| Market revenue in 2023 | USD 1,174.3 million |
| Market revenue in 2030 | USD 2,764.0 million |
| Growth rate | 13% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, Canada accounted for 5.6% of the global recombinant protein therapeutics cdmo market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. recombinant protein therapeutics cdmo market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 16,978.6 million by 2030.
Interferons was the largest segment with a revenue share of 21.48% in 2023. Horizon Databook has segmented the Canada recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
Canada held a market share of 14.6% in North America in 2023. The country seeks to support healthcare innovation by establishing a pathway for advanced therapeutic products. The well established biotechnology sector in Canada is likely to leverage the pipeline of promising treatments. Moreover, several potentially life-saving recombinant protein therapeutics in the country are in various stages of development and clinical trials.
The therapies are designed to combat a range of diseases, including cancer, diabetes, liver disease, rheumatoid arthritis, Alzheimer’s, and many rare conditions. The Canada biologics contract development market is driven by the significantly high investments made by the government and various contracts received by global players. If a company has to outsource to other organizations, it should abide by the PIPEDA Act.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada recombinant protein therapeutics cdmo market size, by type, 2018-2030 (US$M)
Canada Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
